Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017534 | 0.76 | MEN1 (0.54) | MEN1KMT2AMAPTTDP1RAB9A | |
| SCHEMBL1943629 | 0.75 | ALDH1A1 (0.50) | MEN1KMT2AMAPTTDP1RAB9A | |
| SCHEMBL29134217 | 0.72 | ALDH1A1 (0.50) | MEN1KMT2AMAPTTDP1RAB9A | |
| SCHEMBL27812432 | 0.71 | CDK2 (0.56) | MEN1KMT2AMAPTTDP1RAB9A | |
| SCHEMBL21986304 | 0.71 | HPGD (0.50) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL23888750 | 0.70 | HSD17B10 (0.55) | MEN1KMT2AMAPTTDP1RAB9A | |
| Hydrochloric Acid SCHEMBL16246102 | 0.69 | HPGD (0.49) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL867461 | 0.68 | MAPT (0.56) | MEN1KMT2AMAPTTDP1RAB9A | |
| SCHEMBL6194939 | 0.68 | HSD17B10 (0.41) | MEN1KMT2AMAPTTDP1RAB9A | |
| SCHEMBL10492416 | 0.68 | MAPT (0.45) | MEN1KMT2AMAPTTDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055298-B1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10442789-B2 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180086734-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9840493-B2 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160251336-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3055298-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | Sutro Biopharma, Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054658-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442789-B2 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use | DNPEP, SLC1A5, AADAT | MEN1 1459/4885KMT2A 1476/4885MAPT 725/4885 |
| US-20180086734-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | DNPEP, SLC1A5, AADAT | MEN1 1459/4885KMT2A 1476/4885MAPT 725/4885 |
| US-20160251336-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | DNPEP, SLC1A5, AADAT | MEN1 1459/4885KMT2A 1476/4885MAPT 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.